首页> 外文期刊>The Lancet >Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial.
【24h】

Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial.

机译:在资源贫乏的社区中口服米索前列醇预防产后出血:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Postpartum haemorrhage is a major cause of maternal mortality in the developing world. Although effective methods for prevention and treatment of such haemorrhage exist--such as the uterotonic drug oxytocin--most are not feasible in resource-poor settings where many births occur at home. We aimed to investigate whether oral misoprostol, a potential alternative to oxytocin, could prevent postpartum haemorrhage in a community home-birth setting. METHODS: In a placebo-controlled trial undertaken between September, 2002, and December, 2005, 1620 women in rural India were randomised to receive oral misoprostol (n=812) or placebo (n=808) after delivery. 25 auxiliary nurse midwives undertook the deliveries, administered the study drug, and measured blood loss. The primary outcome was the incidence of acute postpartum haemorrhage (defined as > or =500 mL bleeding) within 2 h of delivery. Analysis was by intention-to-treat. The trial was registered with the US clinical trials database (http://www. clinicaltrials.gov) as number NCT00097123. FINDINGS: Oral misoprostol was associated with a significant reduction in the rate of acute postpartum haemorrhage (12.0% to 6.4%, p<0.0001; relative risk 0.53 [95% CI 0.39-0.74]) and acute severe postpartum haemorrhage (1.2% to 0.2%, p<0.0001; 0.20 [0.04-0.91]. One case of postpartum haemorrhage was prevented for every 18 women treated. Misoprostol was also associated with a decrease in mean postpartum blood loss (262.3 mL to 214.3 mL, p<0.0001). Postpartum haemorrhage rates fell over time in both groups but remained significantly higher in the placebo group. Women taking misoprostol had a higher rate of transitory symptoms of chills and fever than the control. INTERPRETATION: Oral misoprostol was associated with significant decreases in the rate of acute postpartum haemorrhage and mean blood loss. The drug's low cost, ease of administration, stability, and a positive safety profile make it a good option in resource-poor settings.
机译:背景:产后出血是发展中国家孕产妇死亡的主要原因。尽管存在预防和治疗此类出血的有效方法-例如子宫内膜缩宫药催产素-但大多数方法在资源贫乏的环境中不可行,在这种情况下,许多婴儿在家中出生。我们旨在调查口服米索前列醇(一种可能是催产素的替代品)是否可以在社区家庭出生的环境中预防产后出血。方法:在2002年9月至2005年12月之间进行的安慰剂对照试验中,印度农村地区的1620名妇女在分娩后随机接受口服米索前列醇(n = 812)或安慰剂(n = 808)。 25名辅助护士助产士进行了分娩,服用了研究药物并测量了失血量。主要结局是分娩后2小时内发生急性产后出血(定义为≥500 mL出血)的发生率。分析是按意向性进行的。该试验已在美国临床试验数据库(http:// www。Clinicaltrials.gov)上注册,编号为NCT00097123。结果:口服米索前列醇与急性产后出血(12.0%至6.4%,p <0.0001;相对危险度0.53 [95%CI 0.39-0.74])和急性重度产后出血(1.2%至0.2)的显着降低相关。 %,p <0.0001; 0.20 [0.04-0.91]。每18名接受治疗的妇女中预防1例产后出血,米索前列醇也与平均产后出血量减少相关(262.3 mL至214.3 mL,p <0.0001)。两组的产后出血率均随时间下降,但在安慰剂组中仍显着较高;服用米索前列醇的妇女出现冷颤和发烧的暂时症状发生率高于对照组。解释:口服米索前列醇与急性发生率的显着降低有关产后出血和平均失血该药物的低成本,易用性,稳定性和积极的安全性使其成为资源贫乏地区的不错选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号